BeiGene

BeiGene Ltd. is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

BeiGene aims to tap the area's life sciences talent pool.

BeiGene Expects To Finish Construction At $700 Million New Jersey Site In 2024

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, is entering a new phase as it continues to build its U.S. presence. The company announced today that the last piece of structural steel will be laid at its Hopewell, NJ campus today. This new facility will provide state-of-the-art commercial-stage U.S.

BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey

BeiGene, Ltd. (BGNE) is technically in oversold territory now, so the heavy selling pressure might have exhausted.

Down -15.66% in 4 Weeks, Here's Why You Should You Buy the Dip in BeiGene, Ltd. (BGNE)

BeiGene, Ltd. (BGNE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.

Here's Why BeiGene, Ltd. (BGNE) is Poised for a Turnaround After Losing -17.02% in 4 Weeks

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today reported financial results for the fourth quarter and full year 2022, recent business highlights, and upcoming milestones.

BeiGene Reports Fourth Quarter and Full Year 2022 Financial Results

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.

BeiGene Receives 10th Approval for PD-1 Inhibitor Tislelizumab in China

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in Cowen's 43rd Annual Healthcare Conference on Monday, March 6th, 2023 with a fireside chat at 11:10 am ET. Live webcasts of these events can be accessed from the investors section of BeiGene's website at http://ir.beigene.com and archived replays will be available for 90 days following the events.

BeiGene to Present at Cowen's 43rd Annual Healthcare Conference

BeiGene (BGNE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for BeiGene (BGNE) This Earnings Season?

Down -14.15% in 4 Weeks, Here's Why BeiGene, Ltd. (BGNE) Looks Ripe for a Turnaround

AbbVie

Align Technology

Baxter

Centene

Exact Sciences

GE HealthCare Technologies Inc

IDEXX Laboratories

Neurocrine Biosciences

Pfizer

After a sub-par performance in 2021, healthcare stocks outperformed the S&P 500 in 2022.

5 Best and Worst Performing Healthcare Stocks in January 2023

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--( BUSINESS WIRE )--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, has released a report highlighting the challenges cancer patients and caregivers face in managing mental and emotional well-being. The data summarized in the report is based on a BeiGene-sponsored study by Cancer Support Community (CSC), a global nonprofit organization that provides free emotional support, navigation, and resources to cancer patients and their loved ones. The report and the newly launched CancerandMentalHealth.com website are part of the company's comprehensive Talk About It: Cancer and Mental Health program, designed to elevate the important intersection of mental health and cancer care.

New Talk About It Resources Aim to Accelerate Integration of Mental Health into Quality Cancer Care

BeiGene's BRUKINSA has recently obtained approval from the FDA for the treatment of small lymphocytic lymphoma and chronic lymphocytic leukemia. BGNE's current valuations are still appealing based on a review of the company's growth and profitability outlook, historical trading multiples and peer comparisons.

BeiGene: Watch FDA Approval And Valuations

Albemarle

CF Industries Holdings

DocuSign

Lucid Group

MongoDB

Okta

Rivian Automotive

Splunk

Unity Software

2022 was a difficult year for the equity market, with the S&P 500 down over 19%, its worst year since 2008 (down 38%).

5 Best and Worst Performing Large-Cap Stocks in December 2022

Alnylam Pharmaceuticals

Bristol-Myers

Royalty Pharma

Teleflex

Universal Health Services

Veeva Systems

Walgreens

Despite inflation making it hard for the healthcare industry to manage its operating costs, there are a few positives that make this sector attractive to investors.

5 Best and Worst Performing Health Care Stocks in December 2022

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--( BUSINESS WIRE )--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has approved its Bruton's tyrosine kinase inhibitor (BTKi) BRUKINSA (zanubrutinib) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

BRUKINSA® Approved in the U.S. for Chronic Lymphocytic Leukemia

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--( BUSINESS WIRE )--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorizations for BRUKINSA (zanubrutinib) in Great Britain for both the treatment of adult patients with chronic lymphocytic leukemia (CLL) and the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.

BRUKINSA® (zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) in Great Britain by MHRA

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--( BUSINESS WIRE )--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the National Reimbursement Drug List (NRDL) released by China's National Healthcare Security Administration (NHSA) has been updated to include four new indications for its PD-1 inhibitor tislelizumab. KYPROLIS® (carfilzomib), a proteosome inhibitor licensed-in from Amgen, is included for the first time and XGEVA® (denosumab), a RANKL inhibitor and another Amgen asset, successfully renewed this year. The updated NRDL will officially take effect on March 1, 2023.

BeiGene Announces Expansion of Coverage on China's National Reimbursement Drug List

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--( BUSINESS WIRE )--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, will share clinical data and patient-reported outcomes for its PD-1 inhibitor, tislelizumab, at the 2023 ASCO Gastrointestinal Cancers Symposium, notably, an oral presentation for interim results of the global pivotal phase 3 trial RATIONALE 305 of tislelizumab in combination with chemotherapy in first-line gastric or gastroesophageal junction (G/GEJ) cancer. At the interim analysis, RATIONALE 305 trial met one of the primary endpoints of overall survival (OS) in patients with G/GEJ whose tumors express PD-L1.

BeiGene Presents New Research from Tislelizumab Global Development Program at 2023 ASCO Gastrointestinal Cancers Symposium

If you are looking for stocks that are well positioned to maintain their recent uptrend, BeiGene, Ltd. (BGNE) could be a great choice.

What Makes BeiGene, Ltd. (BGNE) a Good Fit for 'Trend Investing'

Boeing

Burlington Stores

CrowdStrike

Halliburton

SVB Financial Group

Zscaler

The year 2022 proved to be the worst calendar year for the S&P 500 since 2008.

These Were the 5 Best and Worst Performing Large-Cap Stocks in Q4 2022

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--( BUSINESS WIRE )--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company today announced that the Company will participate in the J.P. Morgan 41st Annual Healthcare Conference on Monday, January 9, 2023 at 1:30 p.m. PT.

BeiGene to Present at the J.P. Morgan 41st Annual Healthcare Conference

Abbott Labs

Amgen

argenx

AstraZeneca

Bayer AG

Biogen

United States Brent Oil Fund LP

BioNTech SE

CSL Ltd

Invesco DB Oil Fund

Daiichi Sankyo Co Ltd

Gilead Sciences

Genmab - ADR

Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X Shares

iShares U.S. Oil & Gas Exploration & Production ETF

Incyte

Johnson & Johnson

Eli Lilly

Merck

Moderna

Novo Nordisk

Novartis

VanEck Vectors Oil Services ETF

iPath Pure Beta Crude Oil ETN

Invesco Dynamic Oil & Gas Services ETF

Reckitt Benckiser Group PLC

Regeneron Pharmaceuticals

Roche Holding AG

Seagen

Takeda Pharmaceutical

ProShares Ultra Bloomberg Crude Oil

United States Oil Fund LP

Vertex Pharmaceuticals

SPDR S&P Oil & Gas Exploration & Production ETF

Medical and energy companies, including oil stocks, lead the list of the 100 best stocks in 2022. The post 100 Best Stocks Of 2022: Oil Stocks And Medicals Shine appeared first on Investor's Business Daily.

100 Best Stocks Of 2022: Oil Stocks And Medicals Shine

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--( BUSINESS WIRE )--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a supplemental biologics license application (sBLA) for tislelizumab in patients with first-line unresectable or metastatic hepatocellular carcinoma (HCC).

BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor Tislelizumab

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--( BUSINESS WIRE )--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) a global biotechnology company, today presented the final progression-free survival (PFS) analysis of the ALPINE trial demonstrating superior efficacy and a favorable cardiac safety profile for patients receiving BRUKINSA ® as compared to IMBRUVICA ® in a global phase 3 trial in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL). These data will be presented (Abstract #LBA-6) during the late-breaking session at the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans and simultaneously published in The New England Journal of Medicine. The paper's lead author Jennifer Brown, M.D., Ph.D., Director, CLL Center at Dana-Farber Cancer Institute will present these data.

BeiGene's BRUKINSA® (zanubrutinib) Demonstrated Superior Progression-Free Survival Over IMBRUVICA® (ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker at ASH

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--( BUSINESS WIRE )--BeiGene, a global biotechnology company, is convening diverse stakeholders to amplify the mental health needs of the cancer community during an event hosted for patient advocates and scientists attending the American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans. In collaboration with Cancer Support Community (CSC), the company will preview new national survey findings1, including that 60 percent of individuals impacted by cancer who experienced emotional distress were not referred to a mental health professional by their cancer care team, and one in five who specifically wanted mental health support did not receive it.

BeiGene Calls for Greater Integration of Mental Health in Cancer Care After New Survey Reveals Gaps/Barriers for Patients and Survivors

News for BeiGene Stock (BGNE)